Skip to main content

Table 3 Summary of treatment-emergent adverse events in the etanercept and placebo groups

From: Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study

  Double blind (week 8) Open label (week 16) Escape arm
Finding Etanercept 50 mg(n  = 42) Placebo(n  = 48) Etanercept 50 mg/etanercept 50 mg(n  = 31) Placebo/etanercept 50 mg(n  = 33) Etanercept 50 mg/etanercept 50 mg(n  = 6) Placebo/etanercept 50 mg(n  = 11)
Any adverse event 34 (81.0) 26 (54.2) 12 (38.7) 17 (51.5) 6 (100.0) 9 (81.8)
Serious adverse event 1 (2.4) 2 (4.2) 0 1 (3.0) 0 0
Adverse event leading to discontinuation 4 (9.5) 0 0 2 (6.1) 1 (16.7) 0
Infections 11 (26.2) 10 (20.8) 6 (19.4) 8 (24.2) 2 (33.3) 4 (36.4)
Serious infections 0 0 0 0 0 0
  1. Data presented as number of patients (%).
\